| It is commonly asserted that in vitro diagnostics is | | | | • Lab Service Commercialization Activities |
| a recession-proof industry. Kalorama Information's | | | | • Lab IT Activity and the Involvement of High |
| lead diagnostic analyst Shara Rosen tests that | | | | Tech Players such as Google and IBM. |
| assumption and provides strategic conclusions in | | | | • Success Strategies That are Working in |
| Shara Rosen's new report In Vitro Diagnostics in a | | | | 2009 |
| Recession. | | | | Shara Rosen goes beyond just assessing the |
| The economic problems that began slowing the | | | | market and presents actions that IVD companies |
| U.S. economy keep spreading, with Europe and | | | | can take to assure growth in uncertain times. The |
| Japan following America into recession. The US is | | | | report has a special focuses on developments in |
| experiencing high unemployment rate and | | | | the United States since this is the largest single |
| increased numbers of uninsured workers. But | | | | market for IVD products, but there is discussion |
| what impact is the downturn having on in vitro | | | | of emerging world markets as well. The following |
| diagnostic companies? What are the best areas of | | | | companies who have engaged in relevant |
| IVD and the best world markets? How should | | | | competitive activities in recent months were |
| companies price and market their products? What | | | | profiled in this report: |
| are key companies in the market doing at this | | | | • Abbott Diagnostics |
| time? Among the topics covered in this report: | | | | • Beckman Coulter Inc. |
| • Current Market Estimates for Major | | | | • Becton, Dickinson and Company (BD) |
| Categories of IVD. | | | | • bioMerieux Inc. |
| • Category Forecasts to 2014 | | | | • Celera Corporation |
| • Hospital Woes, Uninsured Patients, Payor | | | | • Cellestis Ltd |
| Stress, and Other Trends industry observers | | | | • Cepheid |
| need to know about. | | | | • Clarient Inc. (formerly ChromaVision) |
| • Current World Economic Conditions US, | | | | • deCode Genetics Inc. |
| Europe and Emerging Markets | | | | • Genomic Health |
| • Obama Administration Healthcare Reform | | | | • Gen-Probe Inc. |
| Boom or Bust for IVD? | | | | • Immucor, Inc. |
| • Mergers and Acquisitions: Abbot - Ibis, | | | | • Inverness Medical Innovations |
| QIAGEN - Corbett Life Science, J&J / Amic | | | | • Luminex Corporation |
| and several other competitive moves. | | | | • Monogram Biosciences, Inc. |
| • Collaborations: Luminex and BD Tripath, | | | | • Nanogen |
| Geisinger Health System and Celera, Sysmex and | | | | • Ortho Clinical Diagnostics (OCD) |
| Epigenomics and other partnerships enacted as | | | | • Qiagen N.V. |
| companies pool limited resources. | | | | • Quidel Corporation |
| • Market Expansions: StatSensor Creatinine | | | | • Roche Diagnostics |
| Meter (TM), Dako and BMS partnership and | | | | • Seegene, Inc. |
| Others. | | | | • Sequenom, Inc. |
| • New Testing Products Launched: BD Focal | | | | • Siemens Medical Solutions Diagnostics |
| Point, Aureon's Prostate Px+, New Abbott Marker | | | | • Sysmex Corporation |
| for AKI and other new tests. | | | | • Vermillion/Ciphergen Biosystems Inc. |